Drug profile · INN
daridorexant hydrochloride
QUVIVIQ
daridorexant hydrochloride (QUVIVIQ) is a orexin receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — daridorexant hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
daridorexant hydrochloride (QUVIVIQ) is a orexin receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Orexin receptor 1 antagonist
Primary target: Orexin/Hypocretin receptor type 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is daridorexant hydrochloride?
daridorexant hydrochloride (QUVIVIQ) is a orexin receptor 1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for daridorexant hydrochloride?
QUVIVIQ is a marketed brand name for daridorexant hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daridorexant hydrochloride?
daridorexant hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.